Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Equillium, Inc.EQ · Entity 6560 | Director | May 21, 2025 | May 23, 2025 |
| VACCINEX, INC.VCNX · Entity 9673 | Director | May 10, 2024 | May 14, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Equillium, Inc.
Report date May 21, 2025 · Filed May 23, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.39 · Expires 2035-05-20 | Direct | 20,000 |
Reported balance
After 2025-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-21 · Grant · Acquired 20,000 · Balance 20,000 F1: The option vests in twelve equal monthly installments commencing on the grant date of May 21, 2025, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in twelve equal monthly installments commencing on the grant date of May 21, 2025, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.
VACCINEX, INC.
Report date May 10, 2024 · Filed May 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.75 · Expires 2034-05-10 | Direct | 2,685 |
Reported balance
After 2024-05-10 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-05-10 · Grant · Acquired 2,685 · Balance 2,685 F6: Pursuant to the Issuer's Director Compensation Plan, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $10,625 for retainer and meeting fees during the first quarter of 2024. The number of options was calculated in accordance with the Black-Scholes valuation model and all such options are immediately exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.75 | Direct | 10,108 |
Reported balance
After 2024-05-10 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-05-10 · Grant · Acquired 10,108 · Balance 10,108 F7: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 10, 2034 or five years following retirement or cessation of services, whichever occurs first. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1,633.80 | Direct | 36 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance 36 F1: This option expires on May 14, 2029 or five years following retirement or cessation of services, whichever occurs first. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $829.50 | Direct | 74 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 74 F2: This option expires on May 12, 2030 or five years following retirement or cessation of services, whichever occurs first. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $451.50 | Direct | 136 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 136 F3: This option expires on May 9, 2031 or five years following retirement or cessation of services, whichever occurs first. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $235.20 | Direct | 253 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 253 F4: This option expires on May 9, 2032 or five years following retirement or cessation of services, whichever occurs first. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $86.10 | Direct | 684 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 684 F5: This option expires on May 8, 2033 or five years following retirement or cessation of services, whichever occurs first. |
Filing footnotes · ownership attribution and instrument terms
F1: This option expires on May 14, 2029 or five years following retirement or cessation of services, whichever occurs first.
F2: This option expires on May 12, 2030 or five years following retirement or cessation of services, whichever occurs first.
F3: This option expires on May 9, 2031 or five years following retirement or cessation of services, whichever occurs first.
F4: This option expires on May 9, 2032 or five years following retirement or cessation of services, whichever occurs first.
F5: This option expires on May 8, 2033 or five years following retirement or cessation of services, whichever occurs first.
F6: Pursuant to the Issuer's Director Compensation Plan, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $10,625 for retainer and meeting fees during the first quarter of 2024. The number of options was calculated in accordance with the Black-Scholes valuation model and all such options are immediately exercisable.
F7: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 10, 2034 or five years following retirement or cessation of services, whichever occurs first.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2025 Filed May 23, 2025 13:38 UTC | Equillium, Inc. EQ · Entity 6560 | GrantDirector Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001415889-25-014395 · form4-05232025_050515.xml · derivative · entry 1 MANIAN BALA S · CIK 0000941871 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-05-20 F1 · derivative.exercise_date: The option vests in twelve equal monthly installments commencing on the grant date of May 21, 2025, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 19:35 UTC | Equillium, Inc. EQ · Entity 6560 | Disposition to issuerDirector Stock Option (right to buy) · Derivative | 20,000 | Not disclosed Strike: $2.59 | Not disclosed |
DisclosureSEC source: 0001415889-25-004757 · form4-02202025_120250.xml · derivative · entry 10 MANIAN BALA S · CIK 0000941871 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2032-05-23 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F6 · derivative.exercise_date: The option vests in twelve equal monthly installments commencing on the grant date of May 24, 2022, provided, however, that the option will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 19:35 UTC | Equillium, Inc. EQ · Entity 6560 | GrantDirector Stock Option (right to buy) · Derivative | 20,000 | Not disclosed Strike: $0.79 | Not disclosed |
DisclosureSEC source: 0001415889-25-004757 · form4-02202025_120250.xml · derivative · entry 9 MANIAN BALA S · CIK 0000941871 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-05-23 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F6 · derivative.exercise_date: The option vests in twelve equal monthly installments commencing on the grant date of May 24, 2022, provided, however, that the option will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 19:35 UTC | Equillium, Inc. EQ · Entity 6560 | Disposition to issuerDirector Stock Option (right to buy) · Derivative | 20,770 | Not disclosed Strike: $6.55 | Not disclosed |
DisclosureSEC source: 0001415889-25-004757 · form4-02202025_120250.xml · derivative · entry 8 MANIAN BALA S · CIK 0000941871 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,770 shares Expires 2031-05-25 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F5 · derivative.exercise_date: These options vest in twelve equal monthly installments commencing on the grant date of May 26, 2021, provided, however, that the option will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 19:35 UTC | Equillium, Inc. EQ · Entity 6560 | GrantDirector Stock Option (right to buy) · Derivative | 20,770 | Not disclosed Strike: $0.79 | Not disclosed |
DisclosureSEC source: 0001415889-25-004757 · form4-02202025_120250.xml · derivative · entry 7 MANIAN BALA S · CIK 0000941871 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,770 Underlying: Common Stock · 20,770 shares Expires 2031-05-25 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F5 · derivative.exercise_date: These options vest in twelve equal monthly installments commencing on the grant date of May 26, 2021, provided, however, that the option will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 19:35 UTC | Equillium, Inc. EQ · Entity 6560 | Disposition to issuerDirector Stock Option (right to buy) · Derivative | 20,634 | Not disclosed Strike: $3.53 | Not disclosed |
DisclosureSEC source: 0001415889-25-004757 · form4-02202025_120250.xml · derivative · entry 6 MANIAN BALA S · CIK 0000941871 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,634 shares Expires 2030-05-27 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F4 · derivative.exercise_date: The shares subject to this option became fully vested on the grant date of May 28, 2020. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 19:35 UTC | Equillium, Inc. EQ · Entity 6560 | GrantDirector Stock Option (right to buy) · Derivative | 20,634 | Not disclosed Strike: $0.79 | Not disclosed |
DisclosureSEC source: 0001415889-25-004757 · form4-02202025_120250.xml · derivative · entry 5 MANIAN BALA S · CIK 0000941871 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,634 Underlying: Common Stock · 20,634 shares Expires 2030-05-27 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F4 · derivative.exercise_date: The shares subject to this option became fully vested on the grant date of May 28, 2020. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 19:35 UTC | Equillium, Inc. EQ · Entity 6560 | Disposition to issuerDirector Stock Option (right to buy) · Derivative | 24,000 | Not disclosed Strike: $2.80 | Not disclosed |
DisclosureSEC source: 0001415889-25-004757 · form4-02202025_120250.xml · derivative · entry 4 MANIAN BALA S · CIK 0000941871 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,000 shares Expires 2030-05-18 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F3 · derivative.exercise_date: The options vest in twelve equal monthly installments commencing on the grant date of May 19, 2020, provided, however, that the options will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 19:35 UTC | Equillium, Inc. EQ · Entity 6560 | GrantDirector Stock Option (right to buy) · Derivative | 24,000 | Not disclosed Strike: $0.79 | Not disclosed |
DisclosureSEC source: 0001415889-25-004757 · form4-02202025_120250.xml · derivative · entry 3 MANIAN BALA S · CIK 0000941871 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2030-05-18 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F3 · derivative.exercise_date: The options vest in twelve equal monthly installments commencing on the grant date of May 19, 2020, provided, however, that the options will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 19:35 UTC | Equillium, Inc. EQ · Entity 6560 | Disposition to issuerDirector Stock Option (right to buy) · Derivative | 12,000 | Not disclosed Strike: $6.01 | Not disclosed |
DisclosureSEC source: 0001415889-25-004757 · form4-02202025_120250.xml · derivative · entry 2 MANIAN BALA S · CIK 0000941871 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2029-06-10 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1 · derivative.exercise_date: The shares subject to the option vest in twelve equal monthly installments commencing on the grant date of June 11, 2019, provided, however, that the option will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 19:35 UTC | Equillium, Inc. EQ · Entity 6560 | GrantDirector Stock Option (right to buy) · Derivative | 12,000 | Not disclosed Strike: $0.79 | Not disclosed |
DisclosureSEC source: 0001415889-25-004757 · form4-02202025_120250.xml · derivative · entry 1 MANIAN BALA S · CIK 0000941871 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2029-06-10 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1 · derivative.exercise_date: The shares subject to the option vest in twelve equal monthly installments commencing on the grant date of June 11, 2019, provided, however, that the option will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date. Read SEC document |
| May 22, 2024 Filed May 23, 2024 18:00 UTC | Equillium, Inc. EQ · Entity 6560 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001415889-24-014369 · form4-05232024_100515.xml · derivative · entry 1 MANIAN BALA S · CIK 0000941871 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2034-05-22 F1 · derivative.exercise_date: The option vests in twelve equal monthly installments commencing on the grant date of May 22, 2024, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date. Read SEC document |
| May 10, 2024 Filed May 14, 2024 16:33 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 10,108 | $0.00 Strike: $5.75 | $0.00 |
DisclosureSEC source: 0001062993-24-010182 · form4.xml · derivative · entry 7 MANIAN BALA S · CIK 0000941871 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,108 Underlying: Common Stock · 10,108 shares Expires not disclosed F7 · derivative.expiration_date: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 10, 2034 or five years following retirement or cessation of services, whichever occurs first. Read SEC document |
| May 10, 2024 Filed May 14, 2024 16:33 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 2,685 | $3.96 Strike: $5.75 | $10,632.60 |
DisclosureSEC source: 0001062993-24-010182 · form4.xml · derivative · entry 6 MANIAN BALA S · CIK 0000941871 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,685 Underlying: Common Stock · 2,685 shares Expires 2034-05-10 F6 · price: Pursuant to the Issuer's Director Compensation Plan, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $10,625 for retainer and meeting fees during the first quarter of 2024. The number of options was calculated in accordance with the Black-Scholes valuation model and all such options are immediately exercisable. Read SEC document |
| May 22, 2023 Filed May 23, 2023 17:50 UTC | Equillium, Inc. EQ · Entity 6560 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.65 | $0.00 |
DisclosureSEC source: 0001209191-23-031706 · doc4.xml · derivative · entry 1 MANIAN BALA S · CIK 0000941871 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-05-22 F1 · derivative.exercise_date: The option vests in twelve equal monthly installments commencing on the grant date of May 22, 2023, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date. Read SEC document |
| May 11, 2023 Filed May 15, 2023 16:32 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 143,848 | $0.00 Strike: $0.41 | $0.00 |
DisclosureSEC source: 0001062993-23-011112 · form4.xml · derivative · entry 5 MANIAN BALA S · CIK 0000941871 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,848 Underlying: Common Stock · 143,848 shares Expires not disclosed F5 · derivative.expiration_date: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 8, 2033 or five years following retirement or cessation of services, whichever occurs first. Read SEC document |
| May 24, 2022 Filed May 25, 2022 19:50 UTC | Equillium, Inc. EQ · Entity 6560 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001209191-22-031992 · doc4.xml · derivative · entry 1 MANIAN BALA S · CIK 0000941871 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-05-24 F1 · derivative.exercise_date: The option vests in twelve equal monthly installments commencing on the grant date of May 24, 2022, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date. Read SEC document |
| May 12, 2022 Filed May 13, 2022 16:41 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 53,254 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001062993-22-012386 · form4.xml · derivative · entry 4 MANIAN BALA S · CIK 0000941871 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,254 Underlying: Common Stock · 53,254 shares Expires not disclosed F4 · derivative.expiration_date: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 9, 2032 or five years following retirement or cessation of services, whichever occurs first. Read SEC document |
| May 26, 2021 Filed May 28, 2021 18:16 UTC | Equillium, Inc. EQ · Entity 6560 | GrantStock Option (right to buy) · Derivative | 20,770 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-036637 · doc4.xml · derivative · entry 1 MANIAN BALA S · CIK 0000941871 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,770 Underlying: Common Stock · 20,770 shares Expires 2031-05-26 F1 · derivative.exercise_date: These options vest in twelve equal monthly installments commencing on the grant date of May 26, 2021, provided that the options will, in any case, be fully vested on the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2018 Equity Incentive Plan (the "Plan")), through such vesting date and will vest in full upon a Change in Control (as defined in the Plan). Read SEC document |
| May 11, 2021 Filed May 12, 2021 16:26 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 28,586 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0000891839-21-000139 · edgar.xml · derivative · entry 3 MANIAN BALA S · CIK 0000941871 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,586 Underlying: Common Stock · 28,586 shares Expires not disclosed F3 · derivative.expiration_date: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 9, 2031 or five years following retirement or cessation of services, whichever occurs first. Read SEC document |
| May 28, 2020 Filed May 29, 2020 16:30 UTC | Equillium, Inc. EQ · Entity 6560 | GrantStock Option (right to buy) · Derivative | 20,634 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001209191-20-032938 · doc4.xml · derivative · entry 1 MANIAN BALA S · CIK 0000941871 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,634 Underlying: Common Stock · 20,634 shares Expires 2030-05-27 Read SEC document |
| May 19, 2020 Filed May 21, 2020 16:30 UTC | Equillium, Inc. EQ · Entity 6560 | GrantStock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001209191-20-031274 · doc4.xml · derivative · entry 1 MANIAN BALA S · CIK 0000941871 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2030-05-19 F1 · derivative.exercise_date: The options vest in twelve equal monthly installments commencing on the grant date of May 19, 2020, provided, however, that the options will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date. Read SEC document |
| May 14, 2020 Filed May 18, 2020 16:21 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 15,679 | $0.00 Strike: $3.95 | $0.00 |
DisclosureSEC source: 0000891839-20-000120 · edgar.xml · derivative · entry 2 MANIAN BALA S · CIK 0000941871 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,679 Underlying: Common Stock · 15,679 shares Expires not disclosed F2 · derivative.expiration_date: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 12, 2030 or five years following retirement or cessation of services, whichever occurs first. Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 16:37 UTC | Equillium, Inc. EQ · Entity 6560 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $6.01 | $0.00 |
DisclosureSEC source: 0001209191-19-036801 · doc4.xml · derivative · entry 1 MANIAN BALA S · CIK 0000941871 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2029-06-10 F1 · derivative.exercise_date: The shares subject to the option vest in twelve equal monthly installments commencing on the grant date of June 11, 2019, provided, however, that the option will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date. Read SEC document |
| May 15, 2019 Filed May 17, 2019 16:40 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 7,718 | $0.00 Strike: $7.78 | $0.00 |
DisclosureSEC source: 0000891839-19-000069 · edgar.xml · derivative · entry 1 MANIAN BALA S · CIK 0000941871 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,718 Underlying: Common Stock · 7,718 shares Expires not disclosed F1 · derivative.expiration_date: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 14, 2029 or five years following retirement or cessation of services, whichever occurs first. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.